Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment

Table 1 Sequence Dataset

^a This group includes patients who failed to achieve SVR after TVR combination treatment.
^b This group includes patients who failed to achieve SVR after the control PR treatment (i.e., patients who did not receive TVR).
^c The NS5A-NS5B genomic region was not sequenced for PROVE2.

ISSN: 1743-422X